We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Add-On Therapy with Rosiglitazone (RSG)/Metformin (MET) as a Fixed-Dose Combination (FDC) vs RSG plus MET or RSG plus Sulfonylurea (SU) as Separate Pills (SP): Retrospective Study of Outcomes and Costs.
- Authors
Delea, Thomas; Arondekar, Bhakti; Kartashov, Alex; Horblyuk, Ruslan
- Abstract
The article presents the findings of a study that aims to compare healthcare utilization and costs and compliance in diabetes patients receiving monotherapy with metformin (MET) or sulfonylurea (SU) who initiated add-on therapy with rosiglitazone (RSG) as a fixed-dose combination (FDC) or as separate pills (SP). The research suggests that add-on therapy with RSG as FDC improves outcomes and reduces costs compared with RSG plus MET or SU as SPs.
- Subjects
PEOPLE with diabetes; TREATMENT of diabetes; MEDICAL care use; MEDICAL care costs; PATIENT compliance; THERAPEUTICS
- Publication
Diabetes, 2007, Vol 56, pA558
- ISSN
0012-1797
- Publication type
Article